Clinical Features, Diagnosis, Management, and Outcomes of Idiopathic Pulmonary Fibrosis in Korea: Analysis of the Korea IPF Cohort (KICO) Registry
Background The Korea Interstitial Lung Disease Study Group has made a new nationwide idiopathic pulmonary fibrosis (IPF) registry because the routine clinical practice has changed due to new guidelines and newly developed antifibrotic agents in the recent decade. The aim of this study was to describ...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Korean Academy of Tuberculosis and Respiratory Diseases
2022-04-01
|
| Series: | Tuberculosis and Respiratory Diseases |
| Subjects: | |
| Online Access: | http://www.e-trd.org/upload/pdf/trd-2021-0123.pdf |
| _version_ | 1819047222164062208 |
|---|---|
| author | Yangjin Jegal Jong Sun Park Song Yee Kim Hongseok Yoo Sung Hwan Jeong Jin Woo Song Jae Ha Lee Hong Lyeol Lee Sun Mi Choi Young Whan Kim Yong Hyun Kim Hye Sook Choi Jongmin Lee Soo-Taek Uh Tae-Hyung Kim Sang-Heon Kim Won-Yeon Lee Yee Hyung Kim Hyun-kyung Lee Eun Joo Lee Eun Young Heo Sei Hoon Yang Hyung Koo Kang Man Pyo Chung |
| author_facet | Yangjin Jegal Jong Sun Park Song Yee Kim Hongseok Yoo Sung Hwan Jeong Jin Woo Song Jae Ha Lee Hong Lyeol Lee Sun Mi Choi Young Whan Kim Yong Hyun Kim Hye Sook Choi Jongmin Lee Soo-Taek Uh Tae-Hyung Kim Sang-Heon Kim Won-Yeon Lee Yee Hyung Kim Hyun-kyung Lee Eun Joo Lee Eun Young Heo Sei Hoon Yang Hyung Koo Kang Man Pyo Chung |
| author_sort | Yangjin Jegal |
| collection | DOAJ |
| description | Background The Korea Interstitial Lung Disease Study Group has made a new nationwide idiopathic pulmonary fibrosis (IPF) registry because the routine clinical practice has changed due to new guidelines and newly developed antifibrotic agents in the recent decade. The aim of this study was to describe recent clinical characteristics of Korean IPF patients. Methods Both newly diagnosed and following IPF patients diagnosed after the previous registry in 2008 were enrolled. Survival analysis was only conducted for patients diagnosed with IPF after 2016 because antifibrotic agents started to be covered by medical insurance of Korea in October 2015. Results A total of 2,139 patients were analyzed. Their mean age at diagnosis was 67.4±9.3 years. Of these patients, 76.1% were males, 71.0% were ever-smokers, 14.4% were asymptomatic at the time of diagnosis, and 56.9% were at gender-age-physiology stage I. Occupational toxic material exposure was reported in 534 patients. The mean forced vital capacity was 74.6% and the diffusing capacity for carbon monoxide was 63.6%. Treatment with pirfenidone was increased over time: 62.4% of IPF patients were treated with pirfenidone initially. And 79.2% of patients were treated with antifiboritics for more than three months during the course of the disease since 2016. Old age, acute exacerbation, treatment without antifibrotics, and exposure to wood and stone dust were associated with higher mortality. Conclusion In the recent Korean IPF registry, the percentage of IPF patients treated with antifibrotics was increased compared to that in the previous IPF registry. Old age, acute exacerbation, treatment without antifibrotics, and exposure to wood and stone dust were associated with higher mortality. |
| first_indexed | 2024-12-21T10:56:56Z |
| format | Article |
| id | doaj.art-df3157d820ed46cd92db459cf1e09ffb |
| institution | Directory Open Access Journal |
| issn | 1738-3536 2005-6184 |
| language | English |
| last_indexed | 2024-12-21T10:56:56Z |
| publishDate | 2022-04-01 |
| publisher | The Korean Academy of Tuberculosis and Respiratory Diseases |
| record_format | Article |
| series | Tuberculosis and Respiratory Diseases |
| spelling | doaj.art-df3157d820ed46cd92db459cf1e09ffb2022-12-21T19:06:29ZengThe Korean Academy of Tuberculosis and Respiratory DiseasesTuberculosis and Respiratory Diseases1738-35362005-61842022-04-0185218519410.4046/trd.2021.01234607Clinical Features, Diagnosis, Management, and Outcomes of Idiopathic Pulmonary Fibrosis in Korea: Analysis of the Korea IPF Cohort (KICO) RegistryYangjin Jegal0Jong Sun Park1Song Yee Kim2Hongseok Yoo3Sung Hwan Jeong4Jin Woo Song5Jae Ha Lee6Hong Lyeol Lee7Sun Mi Choi8Young Whan Kim9Yong Hyun Kim10Hye Sook Choi11Jongmin Lee12Soo-Taek Uh13Tae-Hyung Kim14Sang-Heon Kim15Won-Yeon Lee16Yee Hyung Kim17Hyun-kyung Lee18Eun Joo Lee19Eun Young Heo20Sei Hoon Yang21Hyung Koo Kang22Man Pyo Chung23 Department of Internal Medicine, Ulsan University Hospital, University of Ulsan, College of Medicine, Ulsan, Korea Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea Division of Pulmonology, Department of Internal Medicine, Institute of Chest Diseases, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea Department of Internal Medicine, Gil Medical Center, Gachon Medical School, Incheon, Korea Division of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Division of Pulmonology, Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea Department of Internal Medicine, Inha University School of Medicine, Incheon, Korea Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea Departement of Respiratory-Allergy and Clinical Immunology, Konkuk University Hospital, Konkuk University School of Medicine, Seoul, Korea Division of Allergy and Pulmonology, Department of Internal Medicine, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Korea Department of Pulmonary and Critical Care Medicine, Kyung Hee Medical Center, Kyung Hee University School of Medicine, Seoul, Korea Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea Division of Pulmonary and Allergy Medicine, Department of Internal Medicine, Soonchunhyang University Hospital, Seoul, Korea Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea Division of Pulmonary Medicine and Allergy, Department of Internal Medicine, Hanyang University Hospital, Hanyang University College of Medicine, Seoul, Korea Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Yonsei University Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, Korea Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, Korea Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea Division of Pulmonary and Critical Care, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea Department of Internal Medicine, Wonkwang University Hospital, Wonkwang University College of Medicine, Iksan, Korea Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Inje University Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KoreaBackground The Korea Interstitial Lung Disease Study Group has made a new nationwide idiopathic pulmonary fibrosis (IPF) registry because the routine clinical practice has changed due to new guidelines and newly developed antifibrotic agents in the recent decade. The aim of this study was to describe recent clinical characteristics of Korean IPF patients. Methods Both newly diagnosed and following IPF patients diagnosed after the previous registry in 2008 were enrolled. Survival analysis was only conducted for patients diagnosed with IPF after 2016 because antifibrotic agents started to be covered by medical insurance of Korea in October 2015. Results A total of 2,139 patients were analyzed. Their mean age at diagnosis was 67.4±9.3 years. Of these patients, 76.1% were males, 71.0% were ever-smokers, 14.4% were asymptomatic at the time of diagnosis, and 56.9% were at gender-age-physiology stage I. Occupational toxic material exposure was reported in 534 patients. The mean forced vital capacity was 74.6% and the diffusing capacity for carbon monoxide was 63.6%. Treatment with pirfenidone was increased over time: 62.4% of IPF patients were treated with pirfenidone initially. And 79.2% of patients were treated with antifiboritics for more than three months during the course of the disease since 2016. Old age, acute exacerbation, treatment without antifibrotics, and exposure to wood and stone dust were associated with higher mortality. Conclusion In the recent Korean IPF registry, the percentage of IPF patients treated with antifibrotics was increased compared to that in the previous IPF registry. Old age, acute exacerbation, treatment without antifibrotics, and exposure to wood and stone dust were associated with higher mortality.http://www.e-trd.org/upload/pdf/trd-2021-0123.pdfidiopathic pulmonary fibrosisnationwide registryantifibrotic agent |
| spellingShingle | Yangjin Jegal Jong Sun Park Song Yee Kim Hongseok Yoo Sung Hwan Jeong Jin Woo Song Jae Ha Lee Hong Lyeol Lee Sun Mi Choi Young Whan Kim Yong Hyun Kim Hye Sook Choi Jongmin Lee Soo-Taek Uh Tae-Hyung Kim Sang-Heon Kim Won-Yeon Lee Yee Hyung Kim Hyun-kyung Lee Eun Joo Lee Eun Young Heo Sei Hoon Yang Hyung Koo Kang Man Pyo Chung Clinical Features, Diagnosis, Management, and Outcomes of Idiopathic Pulmonary Fibrosis in Korea: Analysis of the Korea IPF Cohort (KICO) Registry Tuberculosis and Respiratory Diseases idiopathic pulmonary fibrosis nationwide registry antifibrotic agent |
| title | Clinical Features, Diagnosis, Management, and Outcomes of Idiopathic Pulmonary Fibrosis in Korea: Analysis of the Korea IPF Cohort (KICO) Registry |
| title_full | Clinical Features, Diagnosis, Management, and Outcomes of Idiopathic Pulmonary Fibrosis in Korea: Analysis of the Korea IPF Cohort (KICO) Registry |
| title_fullStr | Clinical Features, Diagnosis, Management, and Outcomes of Idiopathic Pulmonary Fibrosis in Korea: Analysis of the Korea IPF Cohort (KICO) Registry |
| title_full_unstemmed | Clinical Features, Diagnosis, Management, and Outcomes of Idiopathic Pulmonary Fibrosis in Korea: Analysis of the Korea IPF Cohort (KICO) Registry |
| title_short | Clinical Features, Diagnosis, Management, and Outcomes of Idiopathic Pulmonary Fibrosis in Korea: Analysis of the Korea IPF Cohort (KICO) Registry |
| title_sort | clinical features diagnosis management and outcomes of idiopathic pulmonary fibrosis in korea analysis of the korea ipf cohort kico registry |
| topic | idiopathic pulmonary fibrosis nationwide registry antifibrotic agent |
| url | http://www.e-trd.org/upload/pdf/trd-2021-0123.pdf |
| work_keys_str_mv | AT yangjinjegal clinicalfeaturesdiagnosismanagementandoutcomesofidiopathicpulmonaryfibrosisinkoreaanalysisofthekoreaipfcohortkicoregistry AT jongsunpark clinicalfeaturesdiagnosismanagementandoutcomesofidiopathicpulmonaryfibrosisinkoreaanalysisofthekoreaipfcohortkicoregistry AT songyeekim clinicalfeaturesdiagnosismanagementandoutcomesofidiopathicpulmonaryfibrosisinkoreaanalysisofthekoreaipfcohortkicoregistry AT hongseokyoo clinicalfeaturesdiagnosismanagementandoutcomesofidiopathicpulmonaryfibrosisinkoreaanalysisofthekoreaipfcohortkicoregistry AT sunghwanjeong clinicalfeaturesdiagnosismanagementandoutcomesofidiopathicpulmonaryfibrosisinkoreaanalysisofthekoreaipfcohortkicoregistry AT jinwoosong clinicalfeaturesdiagnosismanagementandoutcomesofidiopathicpulmonaryfibrosisinkoreaanalysisofthekoreaipfcohortkicoregistry AT jaehalee clinicalfeaturesdiagnosismanagementandoutcomesofidiopathicpulmonaryfibrosisinkoreaanalysisofthekoreaipfcohortkicoregistry AT honglyeollee clinicalfeaturesdiagnosismanagementandoutcomesofidiopathicpulmonaryfibrosisinkoreaanalysisofthekoreaipfcohortkicoregistry AT sunmichoi clinicalfeaturesdiagnosismanagementandoutcomesofidiopathicpulmonaryfibrosisinkoreaanalysisofthekoreaipfcohortkicoregistry AT youngwhankim clinicalfeaturesdiagnosismanagementandoutcomesofidiopathicpulmonaryfibrosisinkoreaanalysisofthekoreaipfcohortkicoregistry AT yonghyunkim clinicalfeaturesdiagnosismanagementandoutcomesofidiopathicpulmonaryfibrosisinkoreaanalysisofthekoreaipfcohortkicoregistry AT hyesookchoi clinicalfeaturesdiagnosismanagementandoutcomesofidiopathicpulmonaryfibrosisinkoreaanalysisofthekoreaipfcohortkicoregistry AT jongminlee clinicalfeaturesdiagnosismanagementandoutcomesofidiopathicpulmonaryfibrosisinkoreaanalysisofthekoreaipfcohortkicoregistry AT sootaekuh clinicalfeaturesdiagnosismanagementandoutcomesofidiopathicpulmonaryfibrosisinkoreaanalysisofthekoreaipfcohortkicoregistry AT taehyungkim clinicalfeaturesdiagnosismanagementandoutcomesofidiopathicpulmonaryfibrosisinkoreaanalysisofthekoreaipfcohortkicoregistry AT sangheonkim clinicalfeaturesdiagnosismanagementandoutcomesofidiopathicpulmonaryfibrosisinkoreaanalysisofthekoreaipfcohortkicoregistry AT wonyeonlee clinicalfeaturesdiagnosismanagementandoutcomesofidiopathicpulmonaryfibrosisinkoreaanalysisofthekoreaipfcohortkicoregistry AT yeehyungkim clinicalfeaturesdiagnosismanagementandoutcomesofidiopathicpulmonaryfibrosisinkoreaanalysisofthekoreaipfcohortkicoregistry AT hyunkyunglee clinicalfeaturesdiagnosismanagementandoutcomesofidiopathicpulmonaryfibrosisinkoreaanalysisofthekoreaipfcohortkicoregistry AT eunjoolee clinicalfeaturesdiagnosismanagementandoutcomesofidiopathicpulmonaryfibrosisinkoreaanalysisofthekoreaipfcohortkicoregistry AT eunyoungheo clinicalfeaturesdiagnosismanagementandoutcomesofidiopathicpulmonaryfibrosisinkoreaanalysisofthekoreaipfcohortkicoregistry AT seihoonyang clinicalfeaturesdiagnosismanagementandoutcomesofidiopathicpulmonaryfibrosisinkoreaanalysisofthekoreaipfcohortkicoregistry AT hyungkookang clinicalfeaturesdiagnosismanagementandoutcomesofidiopathicpulmonaryfibrosisinkoreaanalysisofthekoreaipfcohortkicoregistry AT manpyochung clinicalfeaturesdiagnosismanagementandoutcomesofidiopathicpulmonaryfibrosisinkoreaanalysisofthekoreaipfcohortkicoregistry |